Ads
related to: us patent validity period for covid vaccine update moderna 1
Search results
Results From The WOW.Com Content Network
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
US firm Moderna sued American competitor Pfizer and its German partner BioNTech for alleged patent infringement in relation to their Comirnaty vaccine, arguing it was due compensation for products ...
A Moderna statement said: “We are pleased that the UK High Court recognised the innovation of Moderna scientists by confirming the validity and infringement of the EP949 patent and that (the ...
But the court ruled another similar patent was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year. Alnylam to appeal ruling ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the ...
Ad
related to: us patent validity period for covid vaccine update moderna 1